Truist Securities Reiterates Buy on Inspire Medical Systems, Maintains $280 Price Target
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Richard Newitter has reiterated a Buy rating on Inspire Medical Systems (NYSE:INSP) and maintained a $280 price target.
March 20, 2024 | 3:44 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Truist Securities reaffirms a Buy rating on Inspire Medical Systems with a $280 price target.
The reiteration of a Buy rating and maintenance of a $280 price target by a reputable analyst like Richard Newitter from Truist Securities could positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100